Infliximab: a biological breakthrough in Crohn's disease therapy

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1247, 2000-01, pp. : 11-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Infliximab maintenance therapy valuable strategy in Crohn's disease.

Inpharma, Vol. 1, Iss. 1313, 2001-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Economic Implications of Biological Therapies for Crohns Disease: Review of Infliximab

By Bodger Keith

PharmacoEconomics, Vol. 23, Iss. 9, 2005-01 ,pp. : 875-888

Adis International

Access to resources Recommend Favorite

New insights into the biological therapy of Crohn’s disease

By Hassan Cesare Zullo Angelo Campo Salvatore MA Morini Sergio

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 4, 2005-04 ,pp. : 409-419

Informa Healthcare

Access to resources Recommend Favorite

Infliximab promising in paediatric Crohn's disease

Inpharma, Vol. 1, Iss. 1391, 2003-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Infliximab: additional benefits in Crohn's disease

Inpharma, Vol. 1, Iss. 1349, 2002-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite